載入...
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection
Pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii (pj) can lead to serious health consequences in patients with an immunocompromised system. Trimethoprim (TMP), used as first-line therapy in combination with sulfamethoxazole, is a selective but only moderately potent pj dihydrofolate red...
Na minha lista:
| 發表在: | Bioorg Med Chem Lett |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6588427/ https://ncbi.nlm.nih.gov/pubmed/31176699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2019.06.004 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|